Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn

In the Media

  • August 18, 2023

What quality controls should be put in place to ensure consistency and purity of cannabinoids for CPG products?

Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions:

  • What is the minimum GMP standard that consumers should expect?
  • What quality controls should CPG companies look for when choosing bioidentical cannabinoids for their products?
  • What quality controls are needed to ensure batch-to-batch consistency?

At this time, the cannabinoid industry is fairly unregulated and is inconsistent from state to state or even local jurisdictions and this means nobody is providing consistent oversight of the broader industry. A consumer wants to be assured they are getting a consistent, high quality product every time they use it.

Some of the standards that consumers should be looking for include ensuring the cannabinoids are made to at least food-grade GMP standards. There also needs to be very tight controls to ensure batch-to-batch consistency. Any large consumer packaged goods company requires the batch-to-batch consistency to ensure their products are produced to the same standard every time.

Full Article

Share this post

Latest Articles

Fierce Biotech Article: Neuroinflammation a Key Underlying Factor in Alzheimer’s Disease Risk

Article featured in Fierce Biotech October 16, 2025 Excerpt:  New findings discussed at the latest Alzheimer’s Association International Conference (AAIC) highlight the risk factors associated

Read More
October 27, 2025

InMed Presents at the 2025 Life Sciences Investor Forum

Video Replay Now Available: InMed’s CEO, Eric A. Adams, presents at the 2025 Life Sciences Investor Forum. In the presentation, which was originally published on

Read More
October 14, 2025

InMed presents INM-901 data at 2025 Alzheimer’s Association International Conference

InMed presented data from its INM-901 Alzheimer’s disease program at the 2025 Alzheimer’s Association International Conference held in Toronto, Canada. The latest study presented in

Read More
August 18, 2025
InMed-logo-mono

#1445 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

  • INM-901 for Alzheimer’s Disease
  • INM-089 for Age-related Macular Degeneration
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Novel Analogs

MANUFACTURING

  • BayMedica – Rare Cannabinoid Ingredients
  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2025 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*